These include enhancing the surface expression of MHC class I-related protein A (MICA), HSPs, and/or exosomes; activating NK cells, CD8+ T cells, and DCs; and augmenting the immune-cell trafficking between the tumor and lymphoid organs (197). The gene discussed is CD8A; the disease is neoplasm.